CHEPLAPHARM Arzneimittel GmbH


This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.


Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

1st December 2022
Earnings Call Q3 2022 Results
29th November 2022
Publication Quarterly Report Q3 2022
1st September 2022
Earnings Call H1 2022 Results
29th August 2022
Publication 1st Half-Year Report 2022
2nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit


The latest from CHEPLAPHARM

CHEPLAPHARM’s successful Capital Markets debut: 780 million euros new lending facilities agreed and thus future financing sources secured

CHPLAPHARM Arzneimittel GmbH has successfully completed the refinancing of existing loans and promissory notes.

The new credit facilities totalling 780 million euros were closed per 12.07.2018 with Deutsche Bank, HSBC and UniCredit using Capital Markets London. The placement with international investors was additionally supported by Commerzbank, DZ Bank and Santander, as well as GCA Altium, Latham & Watkins and Heuking Kühn Lüer Wojtek.

"Following the successful establishment of a global Partner network, CHEPLAPHARM is now able to continue the long-standing success story due to the new financing structure by further scaling the business model," explained Sebastian F. Braun (CEO) after the negotiations were concluded.

The new credit facilities ensure that the group's long-term financing is flexible and sustainably secured. In addition to the return of existing loans and promissory notes, there is a significant amount of additional liquidity available to finance future M&A projects. The new financing structure offers CHEPLAPHARM a significant increase in flexibility at attractive conditions. The London market for long-term loans (TLB market) also offers the option of flexible increases to support future growth.

Contact Investor Relations:
CHEPLAPHARM Arzneimittel GmbH | Jens Remmers | Ziegelhof 24 | 17489 Greifswald | investor-relations(at)

Investor Relations topics

Back to top expand_less